Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Cash from Investing Activities (2016 - 2025)

Mimedx's Cash from Investing Activities history spans 15 years, with the latest figure at -$335000.0 for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 87.89% year-over-year to -$335000.0; the TTM value through Dec 2025 reached -$6.9 million, up 28.14%, while the annual FY2025 figure was -$6.9 million, 28.14% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$335000.0 at Mimedx, up from -$5.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $113000.0 in Q3 2024 and bottomed at -$6.0 million in Q1 2024.
  • The 5-year median for Cash from Investing Activities is -$530500.0 (2021), against an average of -$1.2 million.
  • The largest annual shift saw Cash from Investing Activities surged 117.41% in 2024 before it tumbled 4753.1% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$314000.0 in 2021, then plummeted by 444.27% to -$1.7 million in 2022, then skyrocketed by 71.85% to -$481000.0 in 2023, then plummeted by 475.26% to -$2.8 million in 2024, then skyrocketed by 87.89% to -$335000.0 in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Cash from Investing Activities are -$335000.0 (Q4 2025), -$5.3 million (Q3 2025), and -$887000.0 (Q2 2025).